DAIICHI SANKYO CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,708 JPY | -0.44% |
|
+3.86% | +21.67% |
| Apr. 19 | Middle East Tensions Dent Asian Stock Markets | MT |
| Apr. 10 | Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark | MT |
| Sales 2024 * | 1,580B 10.18B | Sales 2025 * | 1,758B 11.32B | Capitalization | 9,068B 58.41B |
|---|---|---|---|---|---|
| Net income 2024 * | 168B 1.08B | Net income 2025 * | 192B 1.24B | EV / Sales 2024 * | 5.39 x |
| Net cash position 2024 * | 556B 3.58B | Net cash position 2025 * | 599B 3.86B | EV / Sales 2025 * | 4.82 x |
| P/E ratio 2024 * |
54.2
x | P/E ratio 2025 * |
47.2
x | Employees | 17,435 |
| Yield 2024 * |
0.96% | Yield 2025 * |
1.12% | Free-Float | 97.04% |
More Fundamentals
* Assessed data
More news
Latest transcript on Daiichi Sankyo Co., Ltd.
More recommendations
More press releases
More news
| 1 day | +1.42% | ||
| 1 week | +3.80% | ||
| Current month | -1.00% | ||
| 1 month | -3.75% | ||
| 3 months | +7.06% | ||
| 6 months | +12.19% | ||
| Current year | +22.13% |
1 week
4 481.00
4 755.00
1 month
4 443.004 979.00
Current year
3 847.005 173.00
1 year
3 566.005 173.00
3 years
1 981.005 173.00
5 years
1 696.675 173.00
10 years
518.675 173.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sunao Manabe
CEO | Chief Executive Officer | 69 | 07-03-31 |
Hiroyuki Okuzawa
PSD | President | 61 | 17-03-31 |
Ken Takeshita
CTO | Chief Tech/Sci/R&D Officer | - | 21-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sawako Nohara
BRD | Director/Board Member | 66 | 19-05-31 |
Kazuaki Kama
BRD | Director/Board Member | 75 | 19-05-31 |
Sunao Manabe
CEO | Chief Executive Officer | 69 | 07-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 25.16% | 15 M€ | +7.30% | ||
| 4.18% | 251 M€ | +14.82% | ||
| 3.32% | 174 M€ | -.--% | - | |
| 3.32% | 51 M€ | -.--% | - | |
| 3.24% | 15 M€ | +14.64% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 4,708 | -0.44% | 1 178 900 |
| 24-04-24 | 4,729 | +1.42% | 4,048,900 |
| 24-04-23 | 4,663 | +0.65% | 3,096,100 |
| 24-04-22 | 4,633 | -0.06% | 3,202,900 |
| 24-04-19 | 4,636 | +2.20% | 5,970,000 |
Delayed Quote Japan Exchange, April 24, 2024 at 02:00 am EDT
More quotes
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows:
- sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis;
- other (0.2%): primarily real estate activities.
Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).
Sector
Pharmaceuticals
Calendar
2024-04-24
- Q4 2023 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
4,729
JPY
Average target price
5,620
JPY
Spread / Average Target
+18.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +22.13% | 57.77B | |
| +25.61% | 672B | |
| +25.87% | 570B | |
| -5.24% | 360B | |
| +16.49% | 321B | |
| +8.28% | 300B | |
| +7.09% | 217B | |
| -9.12% | 204B | |
| +5.01% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- 4568 Stock
